NewAmsterdam Pharma Company N.V. (NAMS) Expected to Beat Earnings Estimates: Should You Buy?

Core Insights - Wall Street anticipates a year-over-year decline in earnings for NewAmsterdam Pharma Company N.V. (NAMS) due to lower revenues, with a consensus expectation of a quarterly loss of $0.38 per share, reflecting a -111.1% change from the previous year [1][3] - Revenues are projected to be $3.88 million, which is an 86.7% decrease compared to the same quarter last year [3] - The stock's price movement will largely depend on how actual results compare to these estimates, with a potential for upward movement if results exceed expectations [2] Earnings Estimates and Revisions - The consensus EPS estimate has been revised down by 6.95% over the last 30 days, indicating a reassessment by analysts [4] - The Most Accurate Estimate for NewAmsterdam Pharma is higher than the Zacks Consensus Estimate, resulting in a positive Earnings ESP of +19.13%, suggesting a likelihood of beating the consensus EPS estimate [12] Earnings Surprise History - In the last reported quarter, NewAmsterdam Pharma was expected to post a loss of $0.52 per share but actually reported a loss of -$0.15, resulting in a positive surprise of +71.15% [13] - Over the past four quarters, the company has beaten consensus EPS estimates two times [14] Industry Context - In the Zacks Medical - Drugs industry, Corcept Therapeutics is expected to report earnings of $0.18 per share, indicating a year-over-year decline of -56.1%, with revenues expected to be $219.18 million, up 20.1% from the previous year [19] - Corcept's consensus EPS estimate has been revised down by 9.7% over the last 30 days, and it has a negative Earnings ESP of -72.60%, combined with a Zacks Rank of 5 (Strong Sell), making it challenging to predict an earnings beat [20]